Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, with a proprietary pipeline of targeted T-cell Biologics, announces winning the “Licensing Deal of the Year” award at last night’s Scrip Awards 2017.
Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017
Arsanis Announces Closing of Initial Public Offering
Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering.
Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering.